Increased dosing interval of @AstraZeneca @OxfordVacGroup vaccine likely to result in increased efficacy against Symptomatic COVID caused by B.1.351🇿🇦. Reduction in Neutralisation for P.1🇧🇷variant comparable to B.1.1.7🇬🇧, suggesting high efficacy maintained against this variant. pic.twitter.com/q1kySXwqpZ

— Gazman (@TheGazmanRants) March 25, 2021